Phosphagenics signs development agreement with US firm ALZA
07 November, 2005 by Helen SchullerMelbourne's Phosphagenics (ASX:POH) has entered into an agreement with US-based ALZA Corp to determine the feasibility of delivering a number of compounds nominated by ALZA using Phosphagenics' patented transdermal delivery system, TPM-01.
Peptech to step up R&D after profit boost
07 November, 2005 by Ruth BeranSydney-based Peptech (ASX:PTD) expects to boost its R&D spend in the next year, in the wake of a net profit of AUD$25.7 million for the year ended September 30.
Novogen says remuneration vote subject to proxy error
07 November, 2005 by Ruth BeranNovogen (ASX:NRT) has cited a "voting systems error" as the reason why a significant number of proxy votes were cast against the resolution to adopt the company's remuneration report for the year ended June 30 at its AGM in late October.
LabTech to raise $5.5 million, list on ASX
07 November, 2005 by Helen SchullerSouth Australia's LabTech Systems (NSX:LTS) has lodged a prospectus for an IPO to raise up to AUD$5.5 million to progress the development of its MicroStreak technology and assist in moving the company's shares and options from the Newcastle Stock Exchange to the Australian Stock Exchange.
SSH Medical re-lists with Bio-Layer
07 November, 2005 by Ruth BeranSSH Medical (ASX:SSH) re-listed today on the ASX following a capital raising of AUD$4.26 million and the acquisition of unlisted Brisbane-based materials sciences specialist Bio-Layer.
SciGen partner increases investment
04 November, 2005 by Helen SchullerThe two largest shareholders in Singapore-based, ASX-listed biopharmaceutical company SciGen (ASX:SIE), SciTech Medical and Bioton, have entered into a share exchange agreement which may result in Bioton gaining a 44.7 per cent equity share in SciGen.
Australia ranked first as clinical trial location
03 November, 2005 by Ruth BeranAustralia is the number one location to conduct pharmaceutical clinical trials according to an international benchmarking study undertaken by The Economist Intelligence Unit.
How Iatia changed its fortunes by changing its business model
03 November, 2005 by Ruth BeranRuth Beran talks with Iatia boss Charles Laycock about the importance of being smart and flexible in designing a good biotech business model.
ASIC questions Novogen about remuneration vote
02 November, 2005 by Ruth BeranThe Australian Securities and Investments Commission has written to Novogen (ASX:NRT) after the company adopted the company's remuneration report based on a show of hands at its AGM in late October, despite receiving an overwhelming majority of proxies against the resolution.
OPINION: View from the summit
01 November, 2005 by Stuart RobertsSouthern Cross Equities biotech analyst Stuart Roberts was behind the recent DNA, Devices and Dealers conference in Sydney. Here, he explains his passion for hanging out with biotech's true believers.
A super way to invest in biotech
31 October, 2005 by Ruth BeranWhat are the odds that Australians' precious nest eggs be used to invest in something as risky as biotech? Well guess what -- it's already happening, and governments face pressure to free up more superannuation funds, writes Ruth Beran.
Riding the biotech rollercoaster
26 October, 2005 by Fiona RotherhamExpat Kiwi Simon Moroney knows all too well the vagaries of the share market through his listed German biotech company, MorphoSys, writes Fiona Rotherham.
Biotech made simpler: new code aims to help CEOs and investors
25 October, 2005 by Ruth BeranIt's hardly surprising that one of the Australian biotechnology industry's biggest bugbears is a communication gap between companies and their investors.
Solbec chooses initial tumour targets
24 October, 2005 by Helen SchullerSolbec Pharmaceuticals (ASX:SBP) has selected malignant melanoma and metastatic renal cell carcinoma (mRCC) as the first two tumour types for multiple target activity phase II trials of its lead compound Coramsine in the treatment of advanced tumours.
Tenders close for new CRC host
24 October, 2005 by Susan WilliamsonThree Victorian institutes, the MacFarlane Burnet Institute for Medical Research and Public Health, the University of Melbourne and the Victorian Infectious Diseases Reference Laboratory, have applied to host the WHO Collaborative Centre for Reference and Research on Influenza, which is currently based at the CSL site in Parkville, Melbourne.
